Mo, Jiahang Hu, Xiao Gu, Lihu Chen, Bangsheng Khadaroo, Parikshit Shen, Zefeng Dong, Lei Lv, Yuqi Chitumba, Marylin Liu, Jiequan MOESM2 of Smokers or non-smokers: who benefits more from immune checkpoint inhibitors in treatment of malignancies? An up-to-date meta-analysis Additional file 2: Figure S2. Sensitivity analysis of the long-term prognostic outcomes of anti-PD-1/PD-L1 therapy (Non-smoker vs. Smoker). Smoking;Immunotherapy;Immune checkpoint inhibitors;Anti-PD-1/PD-L1;Meta-analysis 2020-01-21
    https://springernature.figshare.com/articles/figure/MOESM2_of_Smokers_or_non-smokers_who_benefits_more_from_immune_checkpoint_inhibitors_in_treatment_of_malignancies_An_up-to-date_meta-analysis/11665002
10.6084/m9.figshare.11665002.v1